Ownership history in Trexquant Investment LP Β· 7 quarters on record
This page tracks every 13F SEC filing in which Trexquant Investment LP reported a position in IMMUNOCORE HLDGS PLC (IMCR). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Trexquant Investment LP underperformed the S&P 500 by β45.2% annually on this IMCR position. Timing score: 60% (3/5 decisions correct). Average cost basis: $41.41. Maximum drawdown during holding period: β54.1%.
β Significantly underperformed the S&P 500 by 45.2% ann.
5 quarters analyzed
β
Decent timing β more right than wrong on entries and exits.
3 of 5 add/trim decisions correct
Best entry: $36.33 (2025 Q3) Β· Worst: $68.32 (2023 Q4)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
5 adds Β· 2 trims. Bought during 1 of 2 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.04% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size